If everything goes as planned, this week will be the busiest for initial public offerings since 2000.
VIDEO ON MSN MONEY
Missed expectations at the discount retailer? No problem.
Costco (COST) is impervious to negativity. Although the discount retailer missed analysts' expectations, investors are taking the news in stride. Anybody who was waiting for a temporary plunge in the stock price in order to take a position will have to wait a little longer.
Fiscal first-quarter net income inched 2.6% higher to $320 million, or 73 cents per share, including charges related to settling an income tax audit related to its Mexican joint venture and a contribution to a coalition supporting the reform of alcoholic beverage laws in Washington state; combined, these charges dinged earnings by about 7 cents per share.
The markets slumped even after the European Central Bank moved forcefully.
The payout isn't much, but it's the first from the automaker since 2006.
Ford (F) said Thursday it has reinstated a quarterly dividend on its stock, and plans to pay out 5 cents per share on a quarterly basis.
The dividend will be the first from the company since 2006, when it faced significant financial difficulties and was forced to take large private loans to keep itself afloat. The decision paid off, as the company's perception seems to be better than competitors General Motors (GM) and Chrysler -- two companies that needed taxpayer loans to prevent outright collapse.
The acquisition is a vote of confidence in Isis Pharmaceuticals' drug development technology.
Isis Pharmacauticals' (ISIS) baby is going to a new home. Pfizer (PFE) is acquiring Excaliard Pharmaceuticals, an Isis spinoff out of Carlsbad, Calif.
Excaliard was founded in 2006 with technology from Isis. This is an excellent example of an Isis satellite partnership program in which it licenses out drug development candidates it doesn't have the internal resources to develop.
Most of the magazine's picks will sound familiar to investors -- and there's a reason for that.
From Apple (AAPL) to Caterpillar (CAT), the picks rely on stable income stocks that Fortune says are undervalued. "Times are uncertain," the magazine says. "Stocks are moving in lockstep. Reliability and income matter more than ever."
When stocks move in lockstep, it's very difficult to pick ones that can rise above the rest of the action. Did Fortune make the right choices? Let's go through the picks:
Winter is the strong period for agricultural chemical stocks, and 2 industry leaders are showing favorable entry points.
By Tom Aspray, MoneyShow.com
As discussed in "The Four Key Seasonal Trends for 2012," research has indicated that many markets show repeating seasonal tendencies. While these tendencies do not necessarily determine price behavior, buying technically strong markets during strong seasonal periods can give traders and investors an additional edge.
As the charts show, this is the peak season for fertilizer and agricultural chemical stocks, and the weekly bottoming action in two of the key fertilizer stocks makes the risk favorable on new long positions.
Changes in the business model appear to be paying off for the online retailing and auctioneering giant.
By Anthony John Agnello, Consumer and Technology Writer
Don't call it a comeback -- eBay (EBAY) has been here for a long time. But the online auctioneer and e-tailer is on the uptick again, and this time, it could stick.
Raymond James analyst Aaron Kessler's upgrade of eBay to "strong buy" gave the stock a 4% bump Monday and it was hanging onto those gains Tuesday. Kessler gave the company a 12-month price target of $39 -- a hefty 25% above current valuations. EBay is currently hovering below its resistance point price of $31.18 (trading midday Thursday at $30.97), having fluctuated between $29 and $33 for months now.
The insurer announced the acquisition of a leading health data analytics provider.
Humana(HUM) announced the acquisition Wednesday of health care analytics company Anvita Health. The financial terms of the deal remain undisclosed.
Anvita, established in San Diego in 2000, analyzes vast amounts of health care data to provide information to help companies improve the quality of their services and reduce costs.
The acquisition is expected to strengthen Humana’s clinical management.
The burger chain's comparable global sales blew away analyst expectations for November.
The Home of the Golden Arches reported that global same-store sales increased 7.4% in November, surpassing the 4.6% gain Wall Street analysts expected. Sales in Europe and the U.S. rose 6.5% each, beating analysts' expectations. Not surprisingly, shares of the Oakbrook, Ill. company, which have risen more than 25% this year, rose 1.4% to $97.75 Thursday morning.
Expedia, Philip Morris and Las Vegas Sands are downgraded to 'neutral.'
Thursday's noteworthy upgrades include:
Few things are as bullish as stocks breaking above the ranges they have traded in, and big-cap names like McDonald's and IBM are hitting levels we’ve never seen before.
Sometimes it hits you like that. You will be watching the ticker go by and you will say, "Holy cow, did I just see a 4 handle on Home Depot (HD)?" Or, "Wait a second, did McDonald's (MCD) just take out $95? Is Verizon (VZ) finally out of the $35 orb? IBM (IBM) about to take out $200? No way!"
That's where we are right now: Stocks are hitting levels we haven't seen before -- not "haven't seen in a while" . . . never before.
CEO Jeff Bezos is focused on a far-reaching strategy, rather than just short-term results.
Amazon.com (AMZN) has been making massive investments in its future at the expense of short-term results.
With Jeff Bezos -- one of the few remaining tech visionaries -- at the helm, we’re willing to bet the online retailer will succeed in its far-reaching strategy.
The biopharmaceutical company's core product strategy is aimed at addressing major unmet medical needs.
Alnylam develops therapeutics based on a biological breakthrough technology known as ribonucleic acid interference (RNAi). Alnylam is currently using this know-how to build a pipeline of drug candidates to treat a wide array of diseases.
Federal regulators nix a proposal to make the pill available without a prescription to minors.
Teva Pharmaceutical (TEVA) hoped to have the first over-the-counter emergency contraceptive available to all ages Wednesday. It failed.
The U.S. Department of Health and Human Services rejected the company's application for Plan B One-Step -- known as the original morning-after pill -- to be available to consumers of all ages without a prescription. A positive verdict would have given Teva an exclusivity advantage it lost back in 2009, when a generic version of its drug hit the market.
The company reportedly is considering an online marketplace and fast-shipping service that may compete with Amazon.
The search giant is reportedly in negotiations with major retailers and shippers to create an online marketplace, taking Amazon (AMZN) head on. If Google's service manages to launch, it would directly compete against Amazon Prime, which provides customers free and quick shipping for a fixed annual fee.
Given the spate of new initiatives at Google, we believe the fast-shipping service will be a little more difficult to tackle, and question whether the company has the stomach for a business that could be very difficult.
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
3 stocks will be in the spotlight Thursday as investors try to make sense of the numbers from the sector.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] Equity indices remain pinned to their lows with the Russell 2000 (-1.1%) showing the largest loss that has placed the small-cap index back below its 200-day moving average (1144). The Russell 2000 has been battling with that key level during the past two weeks and is now on course to finish the month below its 200-day moving average.
For its part, the S&P 500 (-0.8%) has dipped to its 50-day moving average (1953), which represents the first test of that level since ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|